News | April 12, 2025
Morepen to add 1,000 medical representatives
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Strengthening capabilities in Peptide Therapeutics and CDMO services
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Subscribe To Our Newsletter & Stay Updated
